Related Experiment Videos
Mannose-binding lectin (MBL2) polymorphisms and inflammation in hypertensive patients
R Schreiber1, A V Campos-Coelho, L Brandão
1Department of Internal Medicine, University of Campinas, Campinas, Brazil.
International Journal of Immunogenetics
|September 8, 2011
Summary
Mannose binding lectin 2 (MBL2) gene variants may influence hypertension. Specific MBL2 genotypes were linked to reduced inflammation markers in hypertensive individuals from Southern Brazil.
Area of Science:
- Genetics
- Immunology
- Cardiovascular Medicine
Background:
- Hypertension is a major global health concern.
- Inflammation plays a role in hypertension and end-organ damage.
- Mannose binding lectin 2 (MBL2) is an important component of the innate immune system.
Purpose of the Study:
- To investigate the association between MBL2 functional polymorphisms and hypertension prevalence.
- To explore the link between MBL2 genotypes and hypertensive end-organ damage.
- To assess the relationship between MBL2 variants and inflammatory markers in hypertensive patients.
Main Methods:
- Case-control study design.
- Inclusion of 300 hypertensive patients and 313 normotensive controls from Southern Brazil.
- Genotyping of MBL2 functional polymorphisms.
- Measurement of C-reactive protein levels as an inflammatory marker.
Main Results:
- Hypertensive individuals with MBL2 AO/OO genotypes showed lower C-reactive protein levels compared to those with AA genotypes.
- This suggests a potentially lower inflammatory status in these individuals.
- No direct association with end-organ damage was detailed in the abstract.
Conclusions:
- MBL2 functional polymorphisms may be associated with hypertension, potentially through modulation of inflammatory pathways.
- The findings suggest a role for MBL2 in the inflammatory component of hypertension.
- Further research is warranted to elucidate the precise mechanisms and clinical implications.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...